Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.Histopathology|February 28, 2023
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortiumYasodha Natkunam, Daphne de Jong, Pedro Farinha, et al.Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.Molecular Cell|August 26, 2021
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesisChun Gong, Joanna A Krupka, Jie Gao, et al.Cancer Cell|June 4, 2026
Pathogenesis of diffuse large B cell lymphoma proteogenotypesJulius C Enssle, Björn Häupl, Arber Qoku, et al.Leukemia|June 22, 2022
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsRita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, et al.Pageof 3